Aplin Research

Contact

Name: Andrew Aplin, PhD
Positions:
  • Deputy Director for Scientific Strategy
  • Kalbach-Newton Professor in Cancer Research
Position: Department of Pharmacology, Physiology & Cancer Biology

233 S 10th Street
BLSB 1050
Philadelphia, PA 19107

Contact Number(s):

Publications

Recent Publications

SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death

Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

Targeting TEAD-ious resistance

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

Targeting up-regulated cIAP2 in SOX10-deficient drug tolerant melanoma

MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping

Site matters in metastatic melanoma

Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth

Lysosomal lipid peroxidation regulates tumor immunity

Engaging community members in cancer research: an assessment of an NCI-designated cancer center

IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression

Raptinal Induces Gasdermin E-Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma

Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma

Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway

The future of targeted kinase inhibitors in melanoma

Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?

Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma

Packing a Punch against PD-L1

Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma

RAS-mediated tumor stress adaptation and the targeting opportunities it presents

The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma

SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects

Prognostic values of G-protein mutations in metastatic uveal melanoma

Go Back to Aplin Research